Thermo Fisher Scientific Service — Consolidated revenues increased by 4.1% to $4.63B in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 4.1%, from $4.45B to $4.63B. This is a positive signal — higher values indicate stronger performance for this metric.
An increase indicates a growing reliance on service-based business models, which typically offer higher revenue predictability and customer retention compared to product sales.
This metric represents the portion of total corporate revenue generated specifically from service-based offerings within...
Peers in the life sciences and diagnostics sector often report this as a key indicator of 'installed base' monetization and long-term service contract penetration.
tmo_segment_service_revenues_consolidated_revenues| Q2 '21 | Q1 '22 | Q2 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q3 '24 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|
| Value | $2.06B | $3.80B | $3.97B | $4.40B | $4.40B | $4.40B | $4.40B | $4.45B | $4.63B |
| QoQ Change | — | +84.6% | +4.4% | +11.0% | +0.0% | +0.0% | +0.0% | +1.1% | +4.1% |
| YoY Change | — | — | +92.7% | +15.9% | +11.0% | — | — | +1.1% | +4.1% |
We use cookies for analytics. See our Privacy and Cookie Policy.